Literature DB >> 3121223

Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes.

R Zambello1, T Chisesi, C Agostini, L Trentin, M Masciarelli, G Gasparotto, M Vespignani, G Casorati, R Foa, G Semenzato.   

Abstract

In 20 patients with lymphoproliferative disease of granular lymphocytes (LDGL) the cytotoxic in vitro function of peripheral blood mononuclear cells was studied against both NK sensitive (K-562) and NK resistant target cells (Daudi). Cytotoxicity was analysed at resting conditions and after in vitro pre-incubation with recombinant alpha 2-interferon, gamma-interferon and interleukin 2. At resting conditions, a heterogeneous cytotoxic picture was observed against the K-562 targets, with 11 of the 20 patients showing a normal or increased NK activity, and nine an impaired function. Against the Daudi targets, unstimulated cells from all patients displayed a normal cytotoxic activity. Following in vitro stimulation, an increased lytic function against K-562 cells was demonstrated in six of the nine patients with low basal values, in three after boosting with all lymphokines tested and in three with interleukin 2. In three of these six patients incubation with interleukin 2 also produced an increased cytotoxic function against Daudi target cells; this phenomenon may be associated to the lymphokine-activated killer (LAK) system. The importance of investigating the cytotoxic in vitro function in LDGL patients to further characterize the biological features of GL and its relevance to better define the nature of this disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121223      PMCID: PMC1542199     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon.

Authors:  C D Platsoucas; G Fernandes; S L Gupta; S Kempin; B Clarkson; R A Good; S Gupta
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

2.  Abnormal expansions of polyclonal large to small size granular lymphocytes: reactive or neoplastic process?

Authors:  G Semenzato; G Pizzolo; A Ranucci; C Agostini; M Chilosi; I Quinti; G De Sanctis; B Vercelli; F Pandolfi
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

3.  Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells.

Authors:  S C Wright; B Bonavida
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

4.  Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults.

Authors:  T Abo; C A Miller; C M Balch
Journal:  Eur J Immunol       Date:  1984-07       Impact factor: 5.532

5.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

6.  HNK-1 monoclonal antibody (Leu-7) in the identification of abnormal expansions of large granular lymphocytes.

Authors:  F Pandolfi; G Semenzato; G de Rossi; I Quinti; C Guglielmi; A Pezzutto; M Lopez; G Tonietti; L Fontana; T Abo; F Aiuti
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

7.  Differential effects of recombinant human interferon-gamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development.

Authors:  Y Ueno; T Miyawaki; H Seki; A Matsuda; K Taga; H Sato; N Taniguchi
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  A case of chronic lymphocytic leukemia with properties characteristic of natural killer cells.

Authors:  K Itoh; K Tsuchikawa; T Awataguchi; K Shiiba; K Kumagai
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  1 in total

1.  Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes.

Authors:  C Agostini; R Zambello; P Pontisso; A Alberti; L Trentin; F Siviero; R Foà; F Pandolfi; G Semenzato
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.